$ITRM News
Last published 7mo ago
- 7mo agoITRMIterum Therapeutics Announces Filing of Winding Up PetitionGlobeNewswireDUBLIN and CHICAGO, March 27, 2026 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (in Provisional Liquidation) (NASDAQ:ITRM) (the "Company" or "Iterum" or "we"), a company focused on delivering next generation oral and IV
- 9mo agoITRMIterum Therapeutics Provides Business UpdateGlobeNewswire--Expanded Market Access and Patent Protection for ORLYNVAH™ --FDA correspondence regarding the use of ORLYNVAH™ as step-down therapy DUBLIN and CHICAGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Iterum
- 10mo agoITRMApproval of Orlynvah, Nda #213972 (Labeling)FDA Approved DrugsApproval Date: 12/23/2025; Drug Name: Orlynvah, Nda #213972; Active Ingredients: PROBENECID; SULOPENEM ETZADROXIL; Company: Iterum Therap; Submission Status: Approval; Submission Classification: Labeling; Application Number: 213972
- 10mo agoITRMIterum Therapeutics Provides Business UpdateGlobeNewswireDUBLIN and CHICAGO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum" or "we"), a company focused on delivering next generation oral and IV antibiotics to treat
- 11mo agoITRMIterum Therapeutics Provides Business UpdateGlobeNewswireDUBLIN, Ireland and CHICAGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a company focused on delivering next generation oral and IV antibiotics to treat
- 12mo agoITRMIterum Therapeutics Reports Third Quarter 2025 Financial ResultsGlobeNewswire--Commercially Launched ORLYNVAH™ in the United States in August 2025-- --Extended Cash Runway into Q2 2026-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, Nov. 14, 2025
- 1y agoITRMIterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025GlobeNewswireDUBLIN, Ireland and CHICAGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by
- 1y agoITRMIterum Therapeutics to Present Data at IDWeek 2025GlobeNewswireDUBLIN and CHICAGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by
- 1y agoITRMIterum Therapeutics Provides Business UpdateGlobeNewswireDUBLIN and CHICAGO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug
- 1y agoITRMIterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.GlobeNewswireDUBLIN and CHICAGO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant
- 1y agoITRMIterum Therapeutics plc (ITRM) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoITRMIterum Therapeutics Reports Second Quarter 2025 Financial ResultsGlobeNewswire-- Launch of ORLYNVAHTM Expected August 2025— --Cash Runway into 2026-- --Company to host conference call today at 8:30amET-- DUBLIN and CHICAGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc
- 1y agoITRMIterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025GlobeNewswireDUBLIN, Ireland and CHICAGO, July 29, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by
- 1y agoITRMIterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDUBLIN and CHICAGO, July 02, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) ("Iterum" or the "Company"), a company committed to delivering next generation oral and IV antibiotics to address infections
- 1y agoITRMIterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial GrowthGlobeNewswireDUBLIN and CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) ("Iterum" or the "Company"), a company committed to delivering next generation oral and IV antibiotics to address infections
- 1y agoITRMIterum Therapeutics Announces Publication of REASSURE Trial in NEJM EvidenceGlobeNewswireDUBLIN and CHICAGO, June 25, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a company focused on delivering next generation oral and IV antibiotics to treat infections
- 1y agoITRMIterum Therapeutics Announces Partnership for Commercialization ServicesGlobeNewswireU.S. Commercial Launch of ORLYNVAHTM by Q4 2025; First Oral Penem Available in the U.S. Management to host a conference call at 4:30 p.m. ET today DUBLIN and CHICAGO, June 11, 2025 (GLOBE NEWSWIRE) -- Iterum
- 1y agoITRMIterum Therapeutics Announces Extension of Term of Promissory NoteGlobeNewswireDUBLIN and CHICAGO, May 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a company focused on delivering next generation oral and IV antibiotics to treat infections caused
- 1y agoITRMIterum Therapeutics Reports First Quarter 2025 Financial ResultsGlobeNewswire--Preparing for Potential Launch of ORLYNVAHTM by Q4 2025-- --Extended Cash Runway into 2026-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, May 13, 2025 (GLOBE NEWSWIRE) --
- 1y agoITRMIterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025GlobeNewswireDUBLIN, Ireland and CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by
- 1y agoITRMIterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary SharesGlobeNewswireDUBLIN, Ireland and CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by
- 1y agoITRMIterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary SharesGlobeNewswireDUBLIN, Ireland and CHICAGO, April 29, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by
- 1y agoITRMIterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of AntibioticsGlobeNewswireDUBLIN and CHICAGO, April 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant
- 1y agoITRMIterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswire--ORLYNVAHTM Approved by FDA in Q4 2024— --Extended Cash Runway-- --Company to host conference call today at 8:30amET-- DUBLIN and CHICAGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM), a
- 1y agoITRMIterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025GlobeNewswireDUBLIN, Ireland and CHICAGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by
- 1y agoITRMIterum Therapeutics Regains Full Nasdaq ComplianceGlobeNewswireDUBLIN and CHICAGO, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM), (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by
- 1y agoITRMIterum Therapeutics plc (ITRM) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoITRMIterum Therapeutics Reports Third Quarter 2024 Financial ResultsGlobeNewswire-- ORLYNVAHTM Approved by FDA on October 25, 2024— --Company to Host Conference Call Today at 8:30 a.m. EDT-- DUBLIN and CHICAGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM), (Iterum),
- 2y agoITRMIterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024GlobeNewswireDUBLIN and CHICAGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug
- 2y agoITRMIterum Therapeutics plc (ITRM) U.S. FDA Approval of ORLYNVAH Call (Transcript)Earnings Call Transcripts
- 2y agoITRMIterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract InfectionsPR NewswireWHO: Iterum Therapeutics plc (Nasdaq: ITRM) is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of...
- 2y agoITRMIterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract InfectionsGlobeNewswireORLYNVAH™ is the first oral penem approved for use in the U.S. and the second FDA-approved treatment for uUTIs in the past two decades --Company to Host Conference Call on Monday, October 28th at 8:30 a.m.
- 2y agoITRMApproval of Orlynvah, Nda #213972 (Type 1 - New Molecular Entity and Type 4 - New Combination)FDA Approved DrugsApproval Date: 10/25/2024; Drug Name: Orlynvah, Nda #213972; Active Ingredients: SULOPENEM ETZADROXIL;PROBENECID; Company: Iterum Therapeutics Us Ltd; Submission Status: Approval; Submission Classification: Type 1 - New Molecular Entity and Type 4 - New Combination; Application Number: 213972
- 2y agoITRMIterum Therapeutics to Present Data at IDWeek 2024GlobeNewswireDUBLIN and CHICAGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat
- 2y agoITRMIterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual SummitGlobeNewswireDUBLIN and CHICAGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics to treat infections
- 2y agoITRMIterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult WomenGlobeNewswireFDA Decision Expected by PDUFA Goal Date of October 25, 2024 Potential to be First Oral Penem Approved in the U.S. DUBLIN and CHICAGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM)
- 2y agoITRMIterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment ConferenceGlobeNewswireDUBLIN, Ireland and CHICAGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics to treat
- 2y agoITRMIterum Therapeutics plc (ITRM) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoITRMIterum Therapeutics Reports Second Quarter 2024 Financial ResultsGlobeNewswire-- FDA PDUFA Action Date of October 25, 2024; Advisory Committee Meeting on September 9, 2024— --Cash Runway into 2025, including through PDUFA Action Date-- --Company to Host Conference Call Today at 8:30 a.m.
- 2y agoITRMIterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024GlobeNewswireDUBLIN and CHICAGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat
- 2y agoITRMIterum Therapeutics Announces Expiration and Results of Rights OfferingGlobeNewswireDUBLIN and CHICAGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company"), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to
- 2y agoITRMIterum Therapeutics Broadens Patent Estate for Oral SulopenemGlobeNewswireDUBLIN and CHICAGO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat
- 2y agoITRMIterum Therapeutics Commences Rights OfferingGlobeNewswireDUBLIN and CHICAGO, July 22, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company"), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to
- 2y agoITRMIterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract InfectionsGlobeNewswireDUBLIN, Ireland and CHICAGO, June 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics
- 2y agoITRMIterum Therapeutics to Present Data at ASM Microbe 2024GlobeNewswireDUBLIN and CHICAGO, June 05, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat
- 2y agoITRMIterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract InfectionsGlobeNewswireDUBLIN and CHICAGO, May 31, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat
- 2y agoITRMIterum Therapeutics plc (ITRM) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoITRMIterum Therapeutics Reports First Quarter 2024 Financial ResultsGlobeNewswire--NDA Resubmitted; FDA Action Expected in Early Q4 24-- --Cash Runway into 2025, including through Potential FDA Approval-- --Company to Host Conference Call Today at 8:30 a.m. EDT-- DUBLIN, Ireland and
- 2y agoITRMIterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024GlobeNewswireDUBLIN, Ireland and CHICAGO, May 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics
- 2y agoITRMIterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral SulopenemGlobeNewswire--First Oral Penem in the U.S. and Second New Oral Treatment for uUTIs in Over 25 Years, if approved-- --Potential Approval Early Q4 2024-- DUBLIN, Ireland and CHICAGO, April 29, 2024 (GLOBE NEWSWIRE) -- Iterum